Published: May 2026
Notice of Annual General Meeting
The shareholders of AUXESIS PHARMA HOLDING AB (publ), company registration number 559195-6486, are hereby invited to attend the Annual General Meeting.
Date & time
12 June 2026, 15:00
Location
Ramberg Advokater, Kungsgatan 12, Stockholm
Registration deadline
9 June 2026
Register attendance
Register your attendance
Please fill in your name, phone number and email address to register your attendance at the Annual General Meeting.
1. Right to participate in the Annual General Meeting
Shareholders who wish to participate in the Annual General Meeting must be entered as shareholders in the share register maintained by Euroclear Sweden AB six banking days before the meeting and must notify the company of their intention to participate no later than 12:00 on the date stated in the notice.
Shareholders who do not attend the meeting in person may exercise their rights through a proxy with a written, dated and signed power of attorney. The power of attorney may not be older than three months. The notification must state who will represent the shareholder.
A person representing a legal entity must present a registration certificate or other authorization document showing that the person signing the power of attorney is authorized to sign on behalf of the entity.
Shareholders who wish to bring an assistant must notify the company in connection with the registration for the meeting. A maximum of two assistants may be brought.
Authorized signatories do not need to present a power of attorney, but other proxies for individuals or companies must be able to present a valid power of attorney. All participants at the Annual General Meeting must be able to identify themselves upon request.
Registration for participation must be made no later than 9 June 2026 via the form above or by email to auxesis@auxesispharma.com.
The notice is published on the company’s website www.auxesis.se, in the Swedish Official Gazette and through an advertisement in Svenska Dagbladet.
2. Matters at the meeting
2.1 Proposed agenda
- Opening of the meeting
- Election of chairman of the meeting
- Appointment by the chairman of a person to keep the minutes
- Preparation and approval of the voting register
- Election of one or two persons to verify the minutes
- Determination of whether the meeting has been duly convened
- Approval of the agenda
- Presentation of the annual report and the auditor’s report
- Resolutions regarding the following:
- a) Adoption of the income statement and balance sheet
- b) Allocation of the company’s profit or loss according to the adopted balance sheet
- c) Discharge from liability for the members of the board of directors and the chief executive officer
- Determination of fees to the board of directors and, where applicable, the auditors
- Election of the board of directors, chairman of the board and auditors
- Election of nomination committee
- Proposal for authorization for the board of directors to resolve on the issue of 1,000,000 B shares with one-tenth voting rights relative to the A share
- Information from the board of directors and other matters
- Closing of the meeting
The proposal also means that the board of directors, within the scope of the authorization, shall be able to carry out issues of B shares against both cash payment and set-off of debt.
2.2 Proposed resolutions
Shareholders representing more than 51 percent of the voting rights for all shares in the company have announced that, regarding items 10–13, they will propose that the Annual General Meeting resolves:
- That board fees shall be paid in an amount corresponding to one price base amount per board member, with the chairman of the board receiving an additional price base amount. Fees to the auditors shall be paid according to approved invoice until the next Annual General Meeting.
- To support the nomination committee’s proposal.
- That the company shall have a nomination committee consisting of at least two representatives and to support the re-election of Lars Larsson and Helena Adelsten.
- To support the board of directors’ proposal to authorize the board, until the next Annual General Meeting, to resolve on the issue of shares.
3. Documents
The annual report and auditor’s report will be available at the company at least three weeks before the meeting. The complete proposals from the board of directors and the nomination committee will be available at the company no later than three weeks before the meeting.
The annual report, auditor’s report, the nomination committee’s proposal and the board of directors’ proposal will be sent to shareholders upon request.
The documents may be sent either by email or by post. Shareholders should state their preferred distribution method and provide the address to which the documents should be sent when requesting the documents.
Stockholm, 2026-05-04
The Board of Directors of AUXESIS PHARMA HOLDING AB (publ)